Literature DB >> 17559320

Combination therapy reduces self-injurious behavior in a chimpanzee (Pan Troglodytes Troglodytes): a case report.

Sabrina R Bourgeois1, Maribel Vazquez, Kathleen Brasky.   

Abstract

Self-injurious behavior (SIB) remains a severe and intractable abnormal behavior for nonhuman primates in diverse settings and is a significant concern for veterinarians and behavioral scientists. To date, no single pharmacological, behavioral, social, or environmental intervention method has emerged as a reliable permanent cure for treating SIB in all, or even most, individuals. Implementation and evaluation of a combination therapeutic approach to treating SIB for nonhuman primates is rare. In May 2004, a 25-year-old male chimpanzee with severe SIB (M = 2.09 episodes/day, range = 1-4 episodes/day) underwent intensive behavioral intervention that utilized a combination of techniques. The combination therapy approach entailed the following: (a) pharmacological intervention with a gamma-aminobutyric acid (GABA) analogue to treat suspected HIV-related sensory neuropathic pain, (b) positive reinforcement training, and (c) environmental enrichment, as well as social and environmental modification. The severity of SIB warranted immediate implementation of intensive combination therapy rather than a systematic evaluation of the individual treatment options. The individually tailored, multifaceted combination therapy resulted in the virtual elimination of SIB in this chimpanzee over a 2-year period.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17559320     DOI: 10.1080/10888700701313454

Source DB:  PubMed          Journal:  J Appl Anim Welf Sci        ISSN: 1088-8705            Impact factor:   1.440


  9 in total

1.  Survey of Behavioral Indices of Welfare in Research Chimpanzees (Pan troglodytes) in the United States.

Authors:  Mollie A Bloomsmith; Andrea W Clay; Susan P Lambeth; Corrine K Lutz; Sarah D Breaux; Michael L Lammey; Andrea N Franklin; Kim A Neu; Jaine E Perlman; Lisa A Reamer; Mary C Mareno; Steven J Schapiro; Maribel Vazquez; Sabrina R Bourgeois
Journal:  J Am Assoc Lab Anim Sci       Date:  2019-02-14       Impact factor: 1.232

2.  Association of Primate Veterinarians' Guidelines for Assessment of Acute Pain in Nonhuman Primates.

Authors: 
Journal:  J Am Assoc Lab Anim Sci       Date:  2019-11-01       Impact factor: 1.232

3.  Positive reinforcement training moderates only high levels of abnormal behavior in singly housed rhesus macaques.

Authors:  Kate C Baker; Mollie Bloomsmith; Kimberly Neu; Caroline Griffis; Margaret Maloney; Brooke Oettinger; Valerie A M Schoof; Marni Martinez
Journal:  J Appl Anim Welf Sci       Date:  2009       Impact factor: 1.440

4.  Positive reinforcement training as enrichment for singly housed rhesus macaques (Macaca mulatta).

Authors:  K C Baker; M A Bloomsmith; K Neu; C Griffis; M Maloney
Journal:  Anim Welf       Date:  2010-08       Impact factor: 2.244

Review 5.  Nonhuman primate abnormal behavior: Etiology, assessment, and treatment.

Authors:  Corrine K Lutz; Kristine Coleman; Lydia M Hopper; Melinda A Novak; Jaine E Perlman; Ori Pomerantz
Journal:  Am J Primatol       Date:  2022-04-05       Impact factor: 3.014

6.  Signs of mood and anxiety disorders in chimpanzees.

Authors:  Hope R Ferdowsian; Debra L Durham; Charles Kimwele; Godelieve Kranendonk; Emily Otali; Timothy Akugizibwe; J B Mulcahy; Lilly Ajarova; Cassie Meré Johnson
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

7.  How abnormal is the behaviour of captive, zoo-living chimpanzees?

Authors:  Lucy P Birkett; Nicholas E Newton-Fisher
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

8.  Stereotypical behaviors in chimpanzees rescued from the african bushmeat and pet trade.

Authors:  Stacy M Lopresti-Goodman; Marjanne Kameka; Ashlynn Dube
Journal:  Behav Sci (Basel)       Date:  2012-12-27

9.  The beginning of the end for chimpanzee experiments?

Authors:  Andrew Knight
Journal:  Philos Ethics Humanit Med       Date:  2008-06-02       Impact factor: 2.464

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.